Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$12.66 USD

12.66
254,121

+0.02 (0.16%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $12.68 +0.02 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing

by Zacks Equity Research

Bristol-Myers (BMY) Opdivo becomes the first and only FDA-approved PD-1 inhibitor for every four-week dosing.

    Zacks Equity Research

    Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink

    by Zacks Equity Research

    Dermira's (DERM) pipeline candidate, olumacostat glasaretil, fails to meet primary endpoints in two pivotal studies, which evaluate its efficacy for treating moderate-to-severe acne vulgaris.

      Zacks Equity Research

      Pacira (PCRX) Posts Earnings in Q4, Revenues in Line

      by Zacks Equity Research

      Pacira (PCRX) posted earnings in the fourth quarter of 2017 against the estimated loss but posted in line revenues in the quarter.

        Zacks Equity Research

        Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress

        by Zacks Equity Research

        Sarepta (SRPT) beats earnings estimates while missing revenues in the fourth quarter of 2017, based on strong sales of Exondys 51.

          Zacks Equity Research

          Perrigo (PRGO) Surpassed Earnings in Q4, Revenues Down Y/Y

          by Zacks Equity Research

          Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The top line however, drops year over year.

            Zacks Equity Research

            Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y

            by Zacks Equity Research

            Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.

              Zacks Equity Research

              Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4

              by Zacks Equity Research

              Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.

                Zacks Equity Research

                Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y

                by Zacks Equity Research

                Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.

                  Zacks Equity Research

                  AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues

                  by Zacks Equity Research

                  AMAG Pharma (AMAG) beats earnings and misses sales estimates in the fourth quarter of 2017.

                    Zacks Equity Research

                    Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down

                    by Zacks Equity Research

                    Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.